Top

Published in:

01-04-2019 | Letter to the Editor

Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis

Authors: Rafaela Silva Guimarães Gonçalves, Andréa Tavares Dantas, Michelly Cristiny Pereira, Anderson Rodrigues de Almeida, Moacyr J. B. M. Rego, Ivan da Rocha Pitta, Angela Luzia Branco Pinto Duarte, Maira Galdino da Rocha Pitta

Published in: Inflammation | Issue 2/2019

Abstract

Although statins have been successfully administered in the treatment of hypercholesterolemia and cardiovascular disease due to their lipid-lowering and anti-atherosclerotic action, they have shown immunomodulatory effects in several studies with immune-mediated diseases. The aim of this study was to investigate the effects of statins treatment on Th1, Th2, and Th17 cytokines production from stimulated peripheral blood mononuclear cells (PBMCs) obtained from Systemic Sclerosis (SSc) patients. We recruited 21 patients classified according to the American College of Rheumatology criteria for SSc for PBMCs culture analysis. Cytokine levels (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, IL-17A, and IL-17F) were quantified by ELISA or CBA, and patients were assessed for clinical and exam’s variables. Simvastatin and atorvastatin at 50 μM promoted reduction in all cytokine levels with statistical significance, except for IL-6, which had its reduction only induced by the use of simvastatin. Statins, particularly simvastatin, appear to have an immunosuppressive effect in reducing all cytokine secretion levels from PBMCs of SSc in a dose-dependent manner.

Baraut, J., L. Michel, F. Verrecchia, and D. Farge. 2010. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmunity Reviews. 10 (2): 65–73. https://doi.org/10.1016/j.autrev.2010.08.003.CrossRefPubMed

Chizzolini, C., N.C. Brembilla, E. Montanari, and M.E. Truchetet. 2011. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmunity Reviews. 10 (5): 276–281. https://doi.org/10.1016/j.autrev.2010.09.016.CrossRefPubMed

Trifari, S., C.D. Kaplan, E.H. Tran, N.K. Crellin, and H. Spits. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nature Immunology 10 (8): 864–871. https://doi.org/10.1038/ni.1770.CrossRefPubMed

Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Research & Therapy. 2004;6(2):R120–R128. doi:https://doi.org/10.1186/ar1038.

Murata, M., M. Fujimoto, T. Matsushita, Y. Hamaguchi, M. Hasegawa, K. Takehara, K. Komura, and S. Sato. 2008. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? Journal of Dermatological Science. 50 (3): 240–242. https://doi.org/10.1016/j.jdermsci.2008.01.001.CrossRefPubMed

Rossi, M., L. Bazzichi, L. Ghiadoni, I. Mencaroni, F. Franzoni, and S. Bombardieri. 2012. Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients. Rheumatology International 32 (12): 3715–3721. https://doi.org/10.1007/s00296-011-2183-5.CrossRefPubMed

Kim, S.I., D.C. Han, and H.B. Lee. 2000. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. Journal of the American Society of Nephrology : JASN. 11 (1): 80–87.PubMed

Goppelt-Struebe, M., A. Hahn, D. Iwanciw, M. Rehm, and B. Banas. 2001. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). Molecular Pathology : MP. 54 (3): 176–179.CrossRef

Forero-Pena, D.A., and F.R. Gutierrez. 2013. Statins as modulators of regulatory T-cell biology. Mediators of Inflammation 2013: 167086–167010. https://doi.org/10.1155/2013/167086.CrossRefPubMedPubMedCentral

10.

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism 1980;23(5):581–590.

11.

Dantas, A.T., A.R. de Almeida, M. Sampaio, M.F. Cordeiro, L.F. da Rocha Jr., P.S.S. de Oliveira, et al. 2017. Corticosteroid inhibits chemokines production in systemic sclerosis patients. Steroids 127: 24–30. https://doi.org/10.1016/j.steroids.2017.08.012.CrossRefPubMed

12.

Pereira, M.C., P.R. Cardoso, L.F. Da Rocha Jr., M.J. Rego, S.M. Goncalves, F.A. Santos, et al. 2014. Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis. Inflammation Research 63 (4): 309–315. https://doi.org/10.1007/s00011-013-0702-4.CrossRefPubMed

13.

Bessler, H., H. Salman, M. Bergman, R. Straussberg, and M. Djaldetti. 2005. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clinical Immunology 117 (1): 73–77. https://doi.org/10.1016/j.clim.2005.06.014.CrossRefPubMed

14.

Cherfan, P., A. Tompa, A. Wikby, S. Lofgren, and L. Jonasson. 2007. Effects of simvastatin on human T cells in vivo. Atherosclerosis 193 (1): 186–192. https://doi.org/10.1016/j.atherosclerosis.2006.06.022.CrossRefPubMed

15.

Blaschke, S., V. Viereck, G. Schwarz, H.M. Klinger, S. Guerluek, and G.A. Muller. 2009. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 38 (4): 235–239. https://doi.org/10.1080/03009740802572475.CrossRefPubMed

Title: Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis
Authors: Rafaela Silva Guimarães Gonçalves
Andréa Tavares Dantas
Michelly Cristiny Pereira
Anderson Rodrigues de Almeida
Moacyr J. B. M. Rego
Ivan da Rocha Pitta
Angela Luzia Branco Pinto Duarte
Maira Galdino da Rocha Pitta
Publication date: 01-04-2019
Publisher: Springer US
Published in: Inflammation / Issue 2/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-018-0907-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Degradation Products of Polydopamine Restrained Inflammatory Response of LPS-Stimulated Macrophages Through Mediation TLR-4-MYD88 Dependent Signaling Pathways by Antioxidant

Hydrogen-Rich Saline Ameliorates Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice Via the Nrf2-ARE Signaling Pathway

Compound GDC, an Isocoumarin Glycoside, Protects against LPS-Induced Inflammation and Potential Mechanisms In Vitro

MiR-590-3p Attenuates Acute Kidney Injury by Inhibiting Tumor Necrosis Factor Receptor-Associated Factor 6 in Septic Mice

Locally Used Antibiotics for Spinal Infection Prophylaxis and Their Effects on Epidural Fibrosis: an Experimental Laminectomy Study in Rats Using Rifamycin and Gentamycin

Acute Exposure to Diesel-Biodiesel Particulate Matter Promotes Murine Lung Oxidative Stress by Nrf2/HO-1 and Inflammation Through the NF-kB/TNF-α Pathways

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page